To determine the therapeutic potential of the selective IRE1α small molecule inhibitor MKC‐8866 that targets specifically the RNase domain of the IRE1α protein, we first analysed the effect of MKC‐8866 treatment on Xbp1 splicing in pre‐B ALL cells. This evidence concerns the gene XBP1 and acute lymphoblastic leukemia.